{
    "id": 11632,
    "fullName": "ETV6 - RUNX1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ETV6-RUNX1 results from the fusion of ETV6 and RUNX1, which leads to altered transcriptional regulation resulting in preleukemic cells (PMID: 17325341) and demonstrates upregulation of EPOR, leading to increased cell survival (PMID: 21900195).",
            "references": [
                {
                    "id": 3617,
                    "pubMedId": 17325341,
                    "title": "The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17325341"
                },
                {
                    "id": 12154,
                    "pubMedId": 21900195,
                    "title": "ETV6-RUNX1 promotes survival of early B lineage progenitor cells via a dysregulated erythropoietin receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21900195"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2120,
        "geneSymbol": "ETV6",
        "terms": [
            "ETV6",
            "TEL",
            "TEL/ABL",
            "THC5"
        ]
    },
    "variant": "ETV6 - RUNX1",
    "createDate": "09/09/2015",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 861,
                "geneSymbol": "RUNX1",
                "terms": [
                    "RUNX1",
                    "AML1",
                    "AML1-EVI-1",
                    "AMLCR1",
                    "CBF2alpha",
                    "CBFA2",
                    "EVI-1",
                    "PEBP2aB",
                    "PEBP2alpha"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 6165,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "ETV6-RUNX1 is used in the diagnosis of acute lymphocytic leukemia (PMID: 26711002, PMID: 15704129, PMID: 8609706, Guidelines).",
            "molecularProfile": {
                "id": 11683,
                "profileName": "ETV6 - RUNX1"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5331,
                    "pubMedId": 26711002,
                    "title": "Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26711002"
                },
                {
                    "id": 5332,
                    "pubMedId": 15704129,
                    "title": "ETV6/RUNX1 fusion at diagnosis and relapse: some prognostic indications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15704129"
                },
                {
                    "id": 5333,
                    "pubMedId": 8609706,
                    "title": "TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8609706"
                },
                {
                    "id": 5390,
                    "pubMedId": null,
                    "title": "NCCN Guidelines Version 1.2016 Acute Lymphoblastic Leukemia",
                    "url": null
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6166,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In multiple clinical studies, the ETV6-RUNX1 fusion was associated with a favorable prognosis in acute lymphocytic leukemia patients (PMID: 8609706, PMID: 10086740, PMID: 11432885, Guidelines).",
            "molecularProfile": {
                "id": 11683,
                "profileName": "ETV6 - RUNX1"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5333,
                    "pubMedId": 8609706,
                    "title": "TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8609706"
                },
                {
                    "id": 5334,
                    "pubMedId": 10086740,
                    "title": "TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10086740"
                },
                {
                    "id": 5335,
                    "pubMedId": 11432885,
                    "title": "Relapse of TEL-AML1--positive acute lymphoblastic leukemia in childhood: a matched-pair analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11432885"
                },
                {
                    "id": 5390,
                    "pubMedId": null,
                    "title": "NCCN Guidelines Version 1.2016 Acute Lymphoblastic Leukemia",
                    "url": null
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20819,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, knockout of ETV6-RUNX1 in acute lymphocytic leukemia cells combined with Aliqopa (copanlisib) resulted in greater decreased cell viability and phosphorylation of Akt and Mtor compared to knockdown alone in culture (PMID: 31952221).",
            "molecularProfile": {
                "id": 11683,
                "profileName": "ETV6 - RUNX1"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18066,
                    "pubMedId": 31952221,
                    "title": "ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31952221"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11683,
            "profileName": "ETV6 - RUNX1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}